[go: up one dir, main page]

MX2018003982A - Anticuerpos que se unen al receptor cannabinoide 1 (cb1) humano. - Google Patents

Anticuerpos que se unen al receptor cannabinoide 1 (cb1) humano.

Info

Publication number
MX2018003982A
MX2018003982A MX2018003982A MX2018003982A MX2018003982A MX 2018003982 A MX2018003982 A MX 2018003982A MX 2018003982 A MX2018003982 A MX 2018003982A MX 2018003982 A MX2018003982 A MX 2018003982A MX 2018003982 A MX2018003982 A MX 2018003982A
Authority
MX
Mexico
Prior art keywords
antibodies
bind
receiver
human cannabinoid
receptor
Prior art date
Application number
MX2018003982A
Other languages
English (en)
Inventor
Ferrini Roger
Kretz-Rommel Anke
Original Assignee
Bird Rock Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bird Rock Bio Inc filed Critical Bird Rock Bio Inc
Publication of MX2018003982A publication Critical patent/MX2018003982A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Analytical Chemistry (AREA)

Abstract

La presente invención se refiere a anticuerpos y fragmentos de estos novedosos que se unen al receptor cannabinoide 1 (CB1). Los anticuerpos y fragmentos de estos descritos en la presente incluyen anticuerpos humanizados que se unen al receptor CB1. La invención también incluye los usos de los anticuerpos para tratar una enfermedad o trastorno que responde al antagonismo o agonismo del receptor CB1.
MX2018003982A 2015-09-30 2016-09-27 Anticuerpos que se unen al receptor cannabinoide 1 (cb1) humano. MX2018003982A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562235194P 2015-09-30 2015-09-30
PCT/US2016/053927 WO2017058771A1 (en) 2015-09-30 2016-09-27 Antibodies that bind human cannabinoid 1 (cb1) recetor

Publications (1)

Publication Number Publication Date
MX2018003982A true MX2018003982A (es) 2019-01-31

Family

ID=58424250

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018003982A MX2018003982A (es) 2015-09-30 2016-09-27 Anticuerpos que se unen al receptor cannabinoide 1 (cb1) humano.

Country Status (20)

Country Link
US (2) US11421026B2 (es)
EP (1) EP3356833A4 (es)
JP (2) JP2019502651A (es)
KR (1) KR102771076B1 (es)
CN (2) CN108513615B (es)
AU (2) AU2016330471B2 (es)
BR (1) BR112018006633A2 (es)
CA (1) CA3000167A1 (es)
CL (1) CL2018000824A1 (es)
CO (1) CO2018004569A2 (es)
EC (1) ECSP18031407A (es)
HK (1) HK1256286A1 (es)
IL (2) IL300015A (es)
MA (1) MA43049A (es)
MX (1) MX2018003982A (es)
PE (1) PE20181199A1 (es)
RU (1) RU2727018C1 (es)
TW (1) TWI784932B (es)
WO (1) WO2017058771A1 (es)
ZA (1) ZA201802807B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019502651A (ja) * 2015-09-30 2019-01-31 バード・ロック・バイオ・インコーポレイテッドＢｉｒｄ Ｒｏｃｋ Ｂｉｏ， Ｉｎｃ． ヒトカンナビノイド１（ｃｂ１）受容体に結合する抗体
EP3634479A4 (en) 2017-06-09 2021-04-14 President and Fellows of Harvard College Method to identify compounds useful to treat dysregulated lipogenesis, diabetes, and related disorders
MA52504A (fr) * 2018-04-30 2021-04-28 Takeda Pharmaceuticals Co Protéines de liaison du récepteur cannabinoïde de type 1 (cb1) et leurs utilisations
CN111557913B (zh) * 2020-07-07 2022-05-31 中国科学院空天信息创新研究院 靶向癫痫细胞的纳米光敏复合物及调控检测系统
JPWO2023234406A1 (es) 2022-06-03 2023-12-07
CN119585311A (zh) * 2022-07-28 2025-03-07 长春金赛药业有限责任公司 结合大麻素受体cb1的抗体及其用途

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5466579A (en) 1987-12-28 1995-11-14 Psychemedics Corporation Hair analysis method
US5460785A (en) 1989-08-09 1995-10-24 Rhomed Incorporated Direct labeling of antibodies and other protein with metal ions
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
US5817766A (en) 1995-04-05 1998-10-06 Roche Diagnostic Systems, Inc. Reagents for a cannabinoid immunoassay
US20020102208A1 (en) 1999-03-01 2002-08-01 Paul Chinn Radiolabeling kit and binding assay
EP2857516B1 (en) 2000-04-11 2017-06-14 Genentech, Inc. Multivalent antibodies and uses therefor
US7214786B2 (en) * 2000-12-14 2007-05-08 Kovalic David K Nucleic acid molecules and other molecules associated with plants and uses thereof for plant improvement
KR100708398B1 (ko) 2002-03-22 2007-04-18 (주) 에이프로젠 인간화 항체 및 이의 제조방법
ATE393396T1 (de) * 2003-02-18 2008-05-15 Astrazeneca Ab Screening-tests für cannabinoid-ligand-artige modulatoren von gpr55
US7754188B2 (en) 2003-06-30 2010-07-13 Merck Sharp & Dohme Corp. Radiolabeled cannabinoid-1 receptor modulators
US20050095674A1 (en) * 2003-07-23 2005-05-05 Lewis Deborah L. Cannabinoid receptor interacting proteins and methods of use
WO2005023232A2 (en) 2003-09-04 2005-03-17 Affibody Ab Therapeutic, screening and diagnostic methods based on the effect of cb1 receptor modulation on lymphoproliferative disorders.
EP1574211A1 (en) 2004-03-09 2005-09-14 Inserm Use of antagonists of the CB1 receptor for the manufacture of a composition useful for the treatment of hepatic diseases
ITMI20041033A1 (it) 2004-05-24 2004-08-24 Neuroscienze S C A R L Composti farmaceutici
WO2006047417A2 (en) 2004-10-21 2006-05-04 University Of Florida Research Foundation, Inc. Detection of cannabinoid receptor biomarkers and uses thereof
EP1890767A2 (en) 2005-05-27 2008-02-27 Pfizer Products Inc. Combination of a cannabinoid-1- receptor-antagonist and a microsomal triglyceride transfer protein inhibitor for treating obesity or mainataining weight loss
RU2515108C2 (ru) 2005-08-19 2014-05-10 Эббви Инк Иммуноглобулин с двойными вариабельными доменами и его применения
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
WO2007039797A1 (en) * 2005-10-03 2007-04-12 Pfizer Products Inc. Use of cannabinoid receptor-1 antagonist for treating inflammation and arthritis
EP1942724A1 (en) * 2005-11-10 2008-07-16 Arena Pharmaceuticals, Inc. Human g protein-coupled receptor and modulators thereof for the treatment of obesity and conditions related thereto
US8460364B2 (en) 2006-07-20 2013-06-11 Orbusneich Medical, Inc. Bioabsorbable polymeric medical device
WO2008048648A2 (en) 2006-10-17 2008-04-24 Acadia Pharmaceuticals Inc. Cb1-modulating compounds and their use
WO2008147518A1 (en) 2007-05-23 2008-12-04 Merck & Co., Inc. Pyridyl piperidine orexin receptor antagonists
US8293211B2 (en) * 2007-06-11 2012-10-23 Makscientific, Llc CB1 receptor antagonists and uses thereof
EP3059248A1 (en) 2008-05-09 2016-08-24 Abbvie Deutschland GmbH & Co. KG Antibodies to receptor of advanced glycation end products (rage) and uses thereof
FI20085579A0 (fi) 2008-06-12 2008-06-12 Valtion Teknillinen Kannabiskäytön toteaminen
IT1394400B1 (it) 2009-02-25 2012-06-15 Neuroscienze Pharmaness S C Ar L Composizioni farmaceutiche
DK2419447T3 (en) * 2009-04-17 2017-09-25 Immunas Pharma Inc ANTIBODIES THAT SPECIFICALLY BIND TO A BETA OLIGOMER AND USE THEREOF
EE05760B1 (et) * 2010-07-15 2016-03-15 Olegiliich Epshtein Ravimkoostis
WO2012088290A2 (en) 2010-12-22 2012-06-28 Abbott Laboratories Tri-variable domain binding proteins and uses thereof
EP2654792A4 (en) 2010-12-22 2016-05-11 Abbvie Inc HALF IMMUNOGLOBULIN BINDING PROTEINS AND USES THEREOF
GB201102544D0 (en) 2011-02-14 2011-03-30 Randox Lab Ltd Assay
US9435817B2 (en) 2011-02-14 2016-09-06 Randox Laboratories Limited Detection of synthetic cannabinoids
US9441033B2 (en) 2011-02-14 2016-09-13 Randox Laboratories Limited Detection of synthetic cannabinoids
ES2621801T3 (es) * 2011-05-20 2017-07-05 Inserm - Institut National De La Santé Et De La Recherche Médicale Antagonistas del receptor CB1
US8758826B2 (en) 2011-07-05 2014-06-24 Wet Inc. Cannabinoid receptor binding agents, compositions, and methods
CA2860415A1 (en) * 2012-01-09 2013-07-18 Paul L. Prather Use of the aminoalkylindole jwh-073-m4 and related compounds as neutral cb1 recptor antagonists for the treatment of alcoholism, drug abuse, obesity, and obesity-related diseases
CA2874655C (en) * 2012-05-25 2020-11-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of regulating cannabinoid receptor activity-related disorders and diseases
EP2698383B1 (en) 2012-08-14 2020-11-25 Randox Laboratories Ltd. Detection of synthetic Cannabinoids
AU2014302410B2 (en) * 2013-06-26 2019-06-13 Amgen Inc. CB1 receptor antigen-binding proteins and uses thereof
EP3080607A4 (en) 2013-12-12 2017-07-12 AbbVie Stemcentrx LLC Novel anti-dpep3 antibodies and methods of use
KR102731863B1 (ko) * 2014-03-27 2024-11-19 버드 락 바이오, 인크. 인간 카나비노이드 1(cb1) 수용체 결합 항체
JP2019502651A (ja) * 2015-09-30 2019-01-31 バード・ロック・バイオ・インコーポレイテッドＢｉｒｄ Ｒｏｃｋ Ｂｉｏ， Ｉｎｃ． ヒトカンナビノイド１（ｃｂ１）受容体に結合する抗体

Also Published As

Publication number Publication date
US11421026B2 (en) 2022-08-23
IL258337B2 (en) 2023-06-01
WO2017058771A1 (en) 2017-04-06
WO2017058771A8 (en) 2018-04-19
US20180282406A1 (en) 2018-10-04
JP2021176849A (ja) 2021-11-11
ZA201802807B (en) 2022-12-21
KR20180117590A (ko) 2018-10-29
BR112018006633A2 (en) 2018-10-23
TWI784932B (zh) 2022-12-01
CN114805574A (zh) 2022-07-29
AU2016330471A1 (en) 2018-04-26
CA3000167A1 (en) 2017-04-06
ECSP18031407A (es) 2018-05-31
CL2018000824A1 (es) 2019-04-12
US20230159634A1 (en) 2023-05-25
CN108513615A (zh) 2018-09-07
HK1256286A1 (zh) 2019-09-20
IL300015A (en) 2023-03-01
JP2019502651A (ja) 2019-01-31
JP7262522B2 (ja) 2023-04-21
PE20181199A1 (es) 2018-07-23
CN108513615B (zh) 2022-03-08
EP3356833A1 (en) 2018-08-08
KR102771076B1 (ko) 2025-02-24
MA43049A (fr) 2018-08-08
IL258337A (en) 2018-05-31
NZ741496A (en) 2025-05-02
AU2022291658A1 (en) 2023-02-02
CO2018004569A2 (es) 2018-11-22
TW201726733A (zh) 2017-08-01
AU2016330471B2 (en) 2022-09-29
RU2727018C1 (ru) 2020-07-17
EP3356833A4 (en) 2019-04-10

Similar Documents

Publication Publication Date Title
CL2019000799A1 (es) Anticuerpos y fragmentos de los mismos que se unen al receptor cannabinoide 1 (cb1) humano. (divisional solicitud 201602433)
CO2018004569A2 (es) Anticuerpos que se unen al receptor cannabinoide 1 (cb1) humano
MX2020012587A (es) Anticuerpos anti-cd3 y usos de estos.
ECSP18041833A (es) Anticuerpos que se unen específicamente a pd-1 y sus usos
CO2017013356A2 (es) Anticuerpos de factor xi
ECSP18033227A (es) Anticuerpos agonistas que se unen específicamente a CD40 humana y métodos de uso
CL2018000597A1 (es) Métodos para tratar enfermedades inflamatorias
PE20171556A1 (es) Agentes de union a cd123 y usos de estos
UY36905A (es) Anticuerpos neutralizantes de poliomavirus
UY36942A (es) Proteínas de unión a antígeno que activan el receptor de leptina
CL2016002257A1 (es) Anticuerpos anti-mcam y métodos de uso asociados
CL2017003147A1 (es) Moduladores de receptor nuclear
MX389447B (es) Composiciones y métodos para anticuerpos dirigidos a bmp6.
ECSP17080733A (es) Anticuerpos dirigidos a la proteína morfogenética ósea 9 (bmp9) y métodos a partir de estos
CL2017001135A1 (es) Anticuerpos mejorados contra il-6
MX2016009653A (es) Anticuerpos contra glicoproteina f de virus hendra y nipah.
UY36262A (es) Anticuerpos anti proteína similar a angiopoyetina 4 y métodos de uso
MX2020009130A (es) Anticuerpos terapéuticos anti-spla2-gib y los usos de los mismos.
UY37598A (es) Anticuerpos miméticos de fgf21 y usos de los mismos
UY36261A (es) Anticuerpos anti proteína similar a angiopoyetina-4 (angptl4) y métodos de uso
MX391162B (es) Anticuerpos altamente potentes que se unen a receptor de muerte 4 y receptor de muerte 5
EA201791389A1 (ru) Способы и композиции антител, направленных против bmp6
EA202091619A3 (ru) Антитела против tigit